Peripheral modulation of the endocannabinoid system in metabolic disease

Nirajan Shrestha, James S.M. Cuffe, Dana S. Hutchinson, John P. Headrick, Anthony V. Perkins, Andrew J. McAinch, Deanne H. Hryciw

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Dysfunction of the endocannabinoid system (ECS) has been identified in metabolic disease. Cannabinoid receptor 1 (CB1) is abundantly expressed in the brain but also expressed in the periphery. Cannabinoid receptor 2 (CB2) is more abundant in the periphery, including the immune cells. In obesity, global antagonism of overexpressed CB1 reduces bodyweight but leads to centrally mediated adverse psychological outcomes. Emerging research in isolated cultured cells or tissues has demonstrated that targeting the endocannabinoid system in the periphery alleviates the pathologies associated with metabolic disease. Further, peripheral specific cannabinoid ligands can reverse aspects of the metabolic phenotype. This Keynote review will focus on current research on the functionality of peripheral modulation of the ECS for the treatment of obesity. This Keynote review discusses the peripheral modulation of the ECS in liver, adipose tissue, heart, skeletal muscle, gastrointestinal tract, pancreas, kidney and the immuno-inflammatory system.

Original languageEnglish
Pages (from-to)592-604
Number of pages13
JournalDrug Discovery Today
Volume23
Issue number3
DOIs
Publication statusPublished - 1 Mar 2018

Cite this

Shrestha, N., Cuffe, J. S. M., Hutchinson, D. S., Headrick, J. P., Perkins, A. V., McAinch, A. J., & Hryciw, D. H. (2018). Peripheral modulation of the endocannabinoid system in metabolic disease. Drug Discovery Today, 23(3), 592-604. https://doi.org/10.1016/j.drudis.2018.01.029
Shrestha, Nirajan ; Cuffe, James S.M. ; Hutchinson, Dana S. ; Headrick, John P. ; Perkins, Anthony V. ; McAinch, Andrew J. ; Hryciw, Deanne H. / Peripheral modulation of the endocannabinoid system in metabolic disease. In: Drug Discovery Today. 2018 ; Vol. 23, No. 3. pp. 592-604.
@article{6aa0b1779b394a1192df4d16bbc0ef31,
title = "Peripheral modulation of the endocannabinoid system in metabolic disease",
abstract = "Dysfunction of the endocannabinoid system (ECS) has been identified in metabolic disease. Cannabinoid receptor 1 (CB1) is abundantly expressed in the brain but also expressed in the periphery. Cannabinoid receptor 2 (CB2) is more abundant in the periphery, including the immune cells. In obesity, global antagonism of overexpressed CB1 reduces bodyweight but leads to centrally mediated adverse psychological outcomes. Emerging research in isolated cultured cells or tissues has demonstrated that targeting the endocannabinoid system in the periphery alleviates the pathologies associated with metabolic disease. Further, peripheral specific cannabinoid ligands can reverse aspects of the metabolic phenotype. This Keynote review will focus on current research on the functionality of peripheral modulation of the ECS for the treatment of obesity. This Keynote review discusses the peripheral modulation of the ECS in liver, adipose tissue, heart, skeletal muscle, gastrointestinal tract, pancreas, kidney and the immuno-inflammatory system.",
author = "Nirajan Shrestha and Cuffe, {James S.M.} and Hutchinson, {Dana S.} and Headrick, {John P.} and Perkins, {Anthony V.} and McAinch, {Andrew J.} and Hryciw, {Deanne H.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.drudis.2018.01.029",
language = "English",
volume = "23",
pages = "592--604",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "3",

}

Shrestha, N, Cuffe, JSM, Hutchinson, DS, Headrick, JP, Perkins, AV, McAinch, AJ & Hryciw, DH 2018, 'Peripheral modulation of the endocannabinoid system in metabolic disease' Drug Discovery Today, vol. 23, no. 3, pp. 592-604. https://doi.org/10.1016/j.drudis.2018.01.029

Peripheral modulation of the endocannabinoid system in metabolic disease. / Shrestha, Nirajan; Cuffe, James S.M.; Hutchinson, Dana S.; Headrick, John P.; Perkins, Anthony V.; McAinch, Andrew J.; Hryciw, Deanne H.

In: Drug Discovery Today, Vol. 23, No. 3, 01.03.2018, p. 592-604.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Peripheral modulation of the endocannabinoid system in metabolic disease

AU - Shrestha, Nirajan

AU - Cuffe, James S.M.

AU - Hutchinson, Dana S.

AU - Headrick, John P.

AU - Perkins, Anthony V.

AU - McAinch, Andrew J.

AU - Hryciw, Deanne H.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Dysfunction of the endocannabinoid system (ECS) has been identified in metabolic disease. Cannabinoid receptor 1 (CB1) is abundantly expressed in the brain but also expressed in the periphery. Cannabinoid receptor 2 (CB2) is more abundant in the periphery, including the immune cells. In obesity, global antagonism of overexpressed CB1 reduces bodyweight but leads to centrally mediated adverse psychological outcomes. Emerging research in isolated cultured cells or tissues has demonstrated that targeting the endocannabinoid system in the periphery alleviates the pathologies associated with metabolic disease. Further, peripheral specific cannabinoid ligands can reverse aspects of the metabolic phenotype. This Keynote review will focus on current research on the functionality of peripheral modulation of the ECS for the treatment of obesity. This Keynote review discusses the peripheral modulation of the ECS in liver, adipose tissue, heart, skeletal muscle, gastrointestinal tract, pancreas, kidney and the immuno-inflammatory system.

AB - Dysfunction of the endocannabinoid system (ECS) has been identified in metabolic disease. Cannabinoid receptor 1 (CB1) is abundantly expressed in the brain but also expressed in the periphery. Cannabinoid receptor 2 (CB2) is more abundant in the periphery, including the immune cells. In obesity, global antagonism of overexpressed CB1 reduces bodyweight but leads to centrally mediated adverse psychological outcomes. Emerging research in isolated cultured cells or tissues has demonstrated that targeting the endocannabinoid system in the periphery alleviates the pathologies associated with metabolic disease. Further, peripheral specific cannabinoid ligands can reverse aspects of the metabolic phenotype. This Keynote review will focus on current research on the functionality of peripheral modulation of the ECS for the treatment of obesity. This Keynote review discusses the peripheral modulation of the ECS in liver, adipose tissue, heart, skeletal muscle, gastrointestinal tract, pancreas, kidney and the immuno-inflammatory system.

UR - http://www.scopus.com/inward/record.url?scp=85040602029&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2018.01.029

DO - 10.1016/j.drudis.2018.01.029

M3 - Review Article

VL - 23

SP - 592

EP - 604

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 3

ER -